Ikena Oncology Inc Stock News
$1.60
3.90%
today
Nasdaq,
Dec 30, 09:19 pm CET
Ikena Oncology Inc Stock News
Neutral
GlobeNewsWire
●
7 days ago
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Neutral
GlobeNewsWire
●
7 days ago
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Neutral
GlobeNewsWire
●
about 2 months ago
Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter
Neutral
GlobeNewsWire
●
5 months ago
Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
